Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Download Data

Edgewise Therapeutics Inc Equity Repurchase (Common, Net) for the Trailing 12 Months (TTM) ending March 31, 2024: USD 369.00 K

Edgewise Therapeutics Inc Equity Repurchase (Common, Net) is USD 369.00 K for the Trailing 12 Months (TTM) ending March 31, 2024, a -99.72% change year over year. Equity Repurchase (Common, Net) represents the net cash flow from repurchasing or issuing common shares of the company.

Edgewise Therapeutics Inc Equity Repurchase (Common, Net) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 129.84 M, a 26,436.31% change year over year.
Edgewise Therapeutics Inc Equity Repurchase (Common, Net) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -493.00 K, a -100.26% change year over year.
Edgewise Therapeutics Inc Equity Repurchase (Common, Net) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 186.95 M.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends